PDL BioPharma Issues Downbeat Q3 Revenue Forecast

Lisa Levin , Benzinga Staff Writer

September 08, 2011 7:58am Comments

PDL BioPharma Inc (NASDAQ: PDLI) projected downbeat third-quarter revenue.

PDL BioPharma now projects Q3 revenue of $83 million, versus analysts' estimates of $88 million.

PDL BioPharma shares gained 0.17% to $5.80 in after-hours trading.

Posted-In: guidance News Guidance

1	QQQ, XLK: This Nasdaq 100 Signal Last Flashed In 1999—What Came Next Was Insane
2	QQQ, SPY: Federal Reserve Rates 'Justified' Despite Being Highes...
3	KO: Coke's Sweet Switch: Cane Sugar Beverage, Fairlife Ramp O...
4	NEM: World's Largest Gold Miner Newmont Reports Q2 Results...
5	HON: Honeywell Lifts Outlook As Transformation Picks Up Speed
6	INTC: Intel Q2 Earnings: Revenue Beat, EPS Miss, Chipmaker...
7	MA, V: Visa Hit By Japan's First-Ever Antitrust A...

1	NVDA, INTC: Intel CEO Says He's 'Making Hard But Necessary Decisions...
2	DECK, INTC: Intel, Deckers Outdoor, Unitedhealth, Dow, And American Airl...
3	ORCL: Larry Ellison Couldn't Afford His Electric Bill Onc...
4	Trump, Powell Clash Over $3 Billion Federal Reserve Reno...
5	GS: Top 27 Economists Just Delivered a Brutal Reality Chec...
6	INTU: $100 Invested In Intuit 20 Years Ago Would Be Wort...
7	CRH: Here's How Much You Would Have Made Owning...

Market Overview